Download MendeleySynthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor.
Yang, S., Chen, S.J., Hsu, M.F., Wu, J.D., Tseng, C.T., Liu, Y.F., Chen, H.C., Kuo, C.W., Wu, C.S., Chang, L.W., Chen, W.C., Liao, S.Y., Chang, T.Y., Hung, H.H., Shr, H.L., Liu, C.Y., Huang, Y.A., Chang, L.Y., Hsu, J.C., Peters, C.J., Wang, A.H., Hsu, M.C.(2006) J Med Chem 49: 4971-4980
- PubMed: 16884309
- DOI: https://doi.org/10.1021/jm0603926
- Primary Citation of Related Structures:
2GX4 - PubMed Abstract:
A potent SARS coronavirus (CoV) 3CL protease inhibitor (TG-0205221, Ki = 53 nM) has been developed. TG-0205221 showed remarkable activity against SARS CoV and human coronavirus (HCoV) 229E replications by reducing the viral titer by 4.7 log (at 5 microM) for SARS CoV and 5.2 log (at 1.25 microM) for HCoV 229E. The crystal structure of TG-0205221 (resolution = 1.93 A) has revealed a unique binding mode comprising a covalent bond, hydrogen bonds, and numerous hydrophobic interactions. Structural comparisons between TG-0205221 and a natural peptide substrate were also discussed. This information may be applied toward the design of other 3CL protease inhibitors.
Organizational Affiliation:
TaiGen Biotechnology Co., Taipei 114, Taiwan, ROC.
